There was relatively little published data on COVID-19’s effects on patients with chronic kidney disease (CKD). In a tertiary care renal hospital, researchers examined the outcomes of COVID-19 among CKD V patients on hemodialysis (HD), peritoneal dialysis (PD), and dialysis start in terms of length of stay, in-patient death, and 30-day death. A total of 436 CKD V patients with COVID-19 who were hospitalized at the National Kidney and Transplant Institute (NKTI) between March 13, 2020, and August 31, 2020, were included in the research. Survival research using the Kaplan–Meier method was carried out. The Log-Rank test was used to compare the probability of mortality by the group. Statistical significance was defined as a P-value of less than or equal to 0.05. 298 (68%) of the 436 CKD V patients were on HD, 103 (24%) were on PD, and 35 (8%) required dialysis initiation. Overall, 34% of patients died in the hospital; 38% were on HD, 20% on PD, and 37% were on dialysis for the first time. The 30-day mortality rate was 27%, with 32% on HD, 26% on PD, and 16% on the first day of dialysis. The average time between follow-ups was 24 days. The total median time to death among the 137 deaths documented was 10 days; for HD, PD, and dialysis beginning groups, it was 8.5 days, 15.5 days, and 9 days, respectively. HD patients had a considerably higher risk of mortality than PD patients (P<0.00001) and the dialysis initiation group had a considerably greater risk of dying than PD patients (P=0.0234). However, the mortality risk in HD patients was not substantially different from the dialysis initiation group (P=0.63). Patients on HD and dialysis initiation had considerably higher in-hospital and 30-day mortality than patients on PD among CKD V individuals diagnosed with COVID-19 at the NKTI.